comprehensive -WSS

comprehensive

author：explore 2025-09-27 17:03:27 - browse：78

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Head of FDA's diagnostics center, who led through Covid, retires

WSS

Future doctors need a strong humanities education

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Flu vaccine reformulation won't be easy, manufacturers warn

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Prior authorization reform is both possible and imperative

Immunocompromised patients offer clues on chronic Covid

Wikipedia

comprehensive

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Hospital chaplains balance Covid safety with patients’ spiritual needs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Immunocompromised patients offer clues on chronic Covid

The cancer drug shortage isn’t new — and neither are the solutions

FDA early review: GLP

Continuity nursing helped my family in our darkest PICU moments

Cardiologists urge adding sexual orientation, gender identity to health records

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

focus

Head of FDA's diagnostics center, who led through Covid, retires

Nonprofit, backed by Microsoft, to certify AI tools in health care

Boston Scientific acquires urology company Axonics for $3.7 billion

Dana Farber says 6 studies to be retracted and 31 corrected

Arena BioWorks launches in Cambridge to speed drug discovery

Medicare Advantage overpayments discussion gets experts fired up

focus

Wikipedia

hotspot

explore